Compare Danaher Corporation (DHR) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs abrdn Physical Palladium Shares ETF — how do they compare? Danaher Corporation trades at $204.47 (market cap $144.67B), while abrdn Physical Palladium Shares ETF trades at $23.95. The key difference: Danaher Corporation pays a 0.78% dividend while abrdn Physical Palladium Shares ETF pays none, and Danaher Corporation is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| DHR | PALL | |
|---|---|---|
Market Cap | $144.67B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $242.05 | $37.18 |
52-Week Low | $161.91 | $19.96 |
Enterprise Value | $166.88B | — |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $207.44, down 0.87% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company demonstrates solid fundamentals with consistent earnings beats in recent quarters and a healthy 15.95% net income margin. Recent developments include the Masimo acquisition approval and new product launches in the SCIEX division, supporting growth prospects in biotechnology and life sciences segments.
DHR presents a mixed outlook with strong analyst support (69% buy ratings) but faces valuation concerns at a P/E of 36.98. Key opportunities include biotechnology segment growth and strategic acquisitions, while risks involve elevated valuation, competitive pressures, and potential market volatility. The stock trades above the consensus price target of $202.33, suggesting limited near-term upside despite positive fundamentals.
PALL trades at $24.85, down 1.04% over 24 hours. Technical indicators show a bullish trend with moving averages supporting a buy signal, though the RSI suggests potential overbought conditions. The stock underwent a 1:5 split effective May 18, 2026. Recent financial ratios are unavailable, limiting fundamental assessment. News sentiment highlights palladium's price weakness as a potential buying opportunity amid supply risks and industrial demand.
Outlook: PALL presents a speculative opportunity tied to palladium's recovery, with technical strength but limited fundamental data. Risks include commodity price volatility and macroeconomic factors. Investors should weigh the bullish technicals against the absence of current financial metrics and exposure to precious metal market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
